2Q markets preview, tariffs and biotech takeouts — a BioCentury podcast

Outlook for biotech as it looks to continue the growth of 2H25

Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentury This Week podcast, BioCentury’s Stephen Hansen breaks down the near-term and long-term outlook for a biotech industry hoping to continue the growth of 2H25.

BioCentury’s analysts also discuss the impact of the Trump administration’s tariffs on the biopharma industry and last week’s biggest deals: the pending $6.3 billion takeout of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by  Eli Lilly and Co. (NYSE:LLY) and the proposed $5.6 billion acquisition of  Apellis Pharmaceuticals Inc. (NASDAQ:APLS) by  Biogen Inc. (NASDAQ:BIIB).

IQVIA Biotech sponsored this episode of the podcast.

Register now as a delegate or apply to join the 2026 Presenting Company Class before the 26th Bio€quity Europe May 4-6 in Prague sells out.